ARS Pharmaceuticals, Inc. (SPRY) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 9.98 |
| Open | 9.98 |
| Day High | 10.45 |
| Day Low | 9.9 |
| 52-Week High | 18.9 |
| 52-Week Low | 6.66 |
| Volume | 1.27M |
| Average Volume | 1.67M |
| Market Cap | 1.02B |
| PE | -5.14 |
| EPS | -2 |
| Moving Average 50 Days | 8.6 |
| Moving Average 200 Days | 9.38 |
| Change | 0.3 |
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to a
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
GlobeNewswire Inc.
Feb 10, 2026 1:00 PM GMT
-Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more afford
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
GlobeNewswire Inc.
Feb 02, 2026 1:00 PM GMT
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute following expected authorizati